Drug Profile
Research programme: obesity therapeutics - Vastrata
Latest Information Update: 28 Aug 2020
Price :
$50
*
At a glance
- Originator Vastrata
- Class Obesity therapies
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Obesity
Highest Development Phases
- No development reported Obesity
Most Recent Events
- 28 Aug 2020 No recent reports of development identified for research development in Obesity in United Kingdom
- 20 Jul 2016 Research programme: obesity therapeutics - Vastrata is available for licensing as of 20 Jul 2016. http://vastrata.com/
- 20 Jul 2016 Early research in Obesity in United Kingdom (unspecified route)